What do systematic reviews say?

Intravenous vs intraosseous route

The review found no eligible studies for this question.

• Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intravenous vs intraosseous route

• Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 182 participants
  Moderate

Intravenous vs subcutaneous route

Intravenous probably leads to higher insertion failures compared with subcutaneous route (moderate certainty).

• Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease 2015 · Cochrane Headline outcomes only
  RR 14.79 [2.87, 76.08]
  3 studies · 238 participants
  Moderate

Intravenous vs subcutaneous route

• Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 96 participants
  Low

Intravenous vs subcutaneous route

Intravenous may leads to higher dislodgement of device compared with subcutaneous route (low certainty).

• Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease 2015 · Cochrane Headline outcomes only
  RR 3.78 [1.16, 12.34]
  1 study · 67 participants
  Low

Intravenous vs subcutaneous route

The review found no eligible studies for this question.

• Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention probably leads to lower low Hb deferral ‐ at first donation visit after commencement of… (moderate certainty).

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  RR 0.34 [0.21, 0.55]
  4 studies · 1194 participants
  Moderate

Intervention not reported

The intervention probably leads to lower low Hb deferral ‐ after multiple donation visits (moderate certainty).

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  RR 0.25 [0.15, 0.41]
  3 studies · 793 participants
  Moderate

Intervention not reported

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 847 participants
  Moderate

Intervention not reported

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 406 participants
  Moderate

Intervention not reported

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 640 participants
  Moderate

Intervention not reported

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 619 participants
  Moderate

Intervention not reported

The intervention probably leads to higher adverse effects (any) (moderate certainty).

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  RR 1.6 [1.23, 2.07]
  4 studies · 1748 participants
  Moderate